Literature DB >> 8924251

Syncytium-inducing phenotype and zidovudine susceptibility of HIV-1 isolated from post-mortem tissue.

C H McGavin1, S A Land, K L Sebire, D J Hooker, A D Gurusinghe, C J Birch.   

Abstract

OBJECTIVE: To establish the syncytium-inducing (SI) phenotype and zidovudine (ZDV) susceptibility of HIV-1 isolates obtained from autopsy specimens.
METHODS: Isolation of HIV was attempted from autopsy specimens obtained from 76 AIDS patients. Specimens of lymph node, spleen, spinal cord, brain and cerebrospinal fluid (CSF) were processed and cultured with peripheral blood mononuclear cells (PBMC) from seronegative donors. Biological phenotype was determined in a T-lymphocyte line (MT-2). ZDV susceptibility was evaluated in a PBMC-based assay. Sequencing of amino-acid codons in the reverse transcriptase gene previously shown to be associated with ZDV resistance was carried out on a subgroup of isolates.
RESULTS: HIV was recovered from tissue specimens and CSF up to 5 days post-mortem, but recovery rate of infectious virus decreased as the time between autopsy and specimen processing increased. There was a lack of concordance between PBMC isolates and isolates from different tissue sites with respect to SI phenotype. ZDV-resistant virus was isolated from post-mortem specimens of patients who had received long-term ZDV therapy up until or shortly before their death. ZDV-sensitive virus re-emerged in the lymph node of patients who ceased treatment several months prior to death. Phenotypically sensitive virus obtained from lymph node tissue of three patients after a relatively short time off ZDV (4-6 months) retained some of the amino-acid substitutions known to be associated with resistance.
CONCLUSION: The data suggests that ZDV resistance and re-emergence of sensitive virus does not originate in peripheral cells, and that these cells and tissues are seeded with virus present elsewhere, possibly in the germinal centres of the lymph node.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8924251     DOI: 10.1097/00002030-199601000-00007

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  9 in total

1.  In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues.

Authors:  J K Wong; C C Ignacio; F Torriani; D Havlir; N J Fitch; D D Richman
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

2.  A preponderance of CCR5(+) CXCR4(+) mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection.

Authors:  M A Poles; J Elliott; P Taing; P A Anton; I S Chen
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

3.  Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity.

Authors:  P R Gorry; G Bristol; J A Zack; K Ritola; R Swanstrom; C J Birch; J E Bell; N Bannert; K Crawford; H Wang; D Schols; E De Clercq; K Kunstman; S M Wolinsky; D Gabuzda
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

4.  Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate.

Authors:  Paul R Gorry; Joann Taylor; Geoffrey H Holm; Andrew Mehle; Tom Morgan; Mark Cayabyab; Michael Farzan; Hui Wang; Jeanne E Bell; Kevin Kunstman; John P Moore; Steven M Wolinsky; Dana Gabuzda
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

5.  Fitness disadvantage of transitional intermediates contributes to dynamic change in the infecting-virus population during coreceptor switch in R5 simian/human immunodeficiency virus-infected macaques.

Authors:  Madina Shakirzyanova; Wuze Ren; Ke Zhuang; Silvana Tasca; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2010-10-13       Impact factor: 5.103

6.  Analysis of the temporal relationship between human immunodeficiency virus type 1 quasispecies in sequential blood samples and various organs obtained at autopsy.

Authors:  A B van't Wout; L J Ran; C L Kuiken; N A Kootstra; S T Pals; H Schuitemaker
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

7.  Coresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase.

Authors:  G Tachedjian; M French; J Mills
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

8.  Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain.

Authors:  Lachlan Gray; Michael Roche; Melissa J Churchill; Jasminka Sterjovski; Anne Ellett; Pantelis Poumbourios; Shameem Sherieff; Shameem Sheffief; Bin Wang; Nitin Saksena; Damian F J Purcell; Steven Wesselingh; Anthony L Cunningham; Bruce J Brew; Dana Gabuzda; Paul R Gorry
Journal:  J Virol       Date:  2009-03-25       Impact factor: 5.103

9.  Contribution of proteoglycans to human immunodeficiency virus type 1 brain invasion.

Authors:  Michael D Bobardt; Patrick Salmon; Lianchun Wang; Jeffrey D Esko; Dana Gabuzda; Milan Fiala; Didier Trono; Bernadette Van der Schueren; Guido David; Philippe A Gallay
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.